Potential role of tryptophan catabolism in cancer-related cognitive impairment

EROĞLU İ., ÇELİK EROĞLU B.

NUTRITION, cilt.103, 2022 (SCI-Expanded) identifier identifier identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 103
  • Basım Tarihi: 2022
  • Doi Numarası: 10.1016/j.nut.2022.111765
  • Dergi Adı: NUTRITION
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus, Academic Search Premier, PASCAL, Aquatic Science & Fisheries Abstracts (ASFA), CAB Abstracts, CINAHL, EMBASE, Food Science & Technology Abstracts, MEDLINE, Veterinary Science Database
  • Anahtar Kelimeler: Cancer, Cognitive, Impairment, Breast, Tryptophan, BREAST-CANCER, INDOLEAMINE 2,3-DIOXYGENASE, KYNURENINE PATHWAY, ADJUVANT CHEMOTHERAPY, HIPPOCAMPAL, INHIBITION, DYSFUNCTION, METABOLISM, INDUCTION, THERAPY
  • Hacettepe Üniversitesi Adresli: Evet

Özet

Oncology may be the most rapidly expanding field in medicine, with several innovative diagnostic and thera-peutic procedures appearing daily. Advances in oncology have improved the survival rate for patients with cancer and promoting quality of life is now one of the goals in the care of these patients. Patients face a vari-ety of disease-and treatment-related side effects, including anorexia, nausea, vomiting, recurring infections, and sleep difficulties. Cancer-related cognitive impairment (CRCI) is an overlooked clinical condition found in oncologic practice, particularly in patients with breast cancer. Although several potential mechanisms for CRCI have been hypothesized, to our knowledge, the exact mechanism is still unknown. Alterations in the tryptophan kynurenine pathway have been shown to impair cognitive skills in several mental illnesses. How-ever, its possible function in CRCI has yet to be investigated. The aim of this was to examine the possible interactions between tryptophan catabolism and CRCI.(c) 2022 Elsevier Inc. All rights reserved.